Neuland Laboratories Limited has informed the Exchange that Record date for the purpose of Dividend is 18-Jul-2025.
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.7 pts less than Nifty Smallcap 250 and 7.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Neuland Laboratories' Board approved audited financial results for FY25 with consolidated revenue from operations at Rs. 1,476.84 crores, down about 5% from Rs. 1,558.58 crores in FY24. Consolidated net profit stood at Rs. 260.11 crores versus Rs. 300.08 crores in FY24, with EPS at Rs. 202.74 (vs Rs. 233.89). The results include an exceptional gain of Rs. 76.40 crores from the sale of an investment property in Hyderabad; profit before exceptional items actually fell more sharply. The Board recommended a final dividend of Rs. 12 per share (120%) on a face value of Rs. 10 for FY25. The record date for eligibility is July 18, 2025 and the 41st AGM is on July 30, 2025. Additionally, Mr. Davuluri Saharsh Rao has been re-appointed as Vice Chairman & Managing Director for five years effective June 1, 2025.
Investors who buy shares before the ex-date will receive the Rs. 12 final dividend, providing some income support despite a weak operating year marked by lower revenue and earnings. The decline in core profitability, excluding the one-time property sale gain, may pressure the stock in the near term, while continuity in leadership with the Saharsh Rao re-appointment signals stability.